

JAC SUPPLEMENT PREFACE

The global dissemination of carbapenemase-producing Enterobacterales (CPE) over the last two decades has become a worldwide public health concern. Accumulating resistance of enteric Gram-negative bacteria to all but the last-line antibiotics threatens our ability not only to treat common infections, but also the safety of invasive surgical or immunosuppressive treatments that require effective antimicrobial prophylaxis.

Fortunately, a number of new antibiotic and β -lactamase-inhibitor combinations gaining regulatory approval over the last five years have proven to be more effective with less toxicity than colistin-based regimens. Nevertheless, the efficacy of many new β -lactamase inhibitors varies from one region to the next depending on the types of carbapenemase in circulation and emerging resistance to newer agents.

Therefore, it is timely that in this *JAC* Supplement, Paul and colleagues have taken the opportunity to review the current evidence for management of KPC-producing *Klebsiella pneumoniae*. The topics span from infection control, surgical prophylaxis, and clinical outcomes in ICU and transplant populations to the evaluation of antimicrobial stewardship practices and review of data supporting newer treatment options.

We hope this supplement will be a valued resource for healthcare professionals faced with managing CPE infections, as well as those who take an academic interest in them and we envisage it will prompt further discussion on the research priorities needed to address this omnipresent resistant threat.

Russell Lewis, Associate Professor, Infectious Diseases

Infectious Diseases Hospital, S. Orsola-Malpighi IRCSS

Department of Medical and Surgical Sciences, University of Bologna

Conflicts of Interest: Research support: Merck & Co, Speakers and advisory: Gilead, Cidara therapeutics

Virve I. Enne, Centre for Clinical Microbiology, University College London

COI **VE**: Speaking honoraria, consultancy fees and in-kind contributions from several diagnostic companies including Curetis GmbH, bioMérieux and Oxford Nanopore.

Luis Ostrosky-Zeichner, Division of Infectious Diseases, McGovern Medical School

COI: Research funds, speaking and/or consulting honoraria from the following companies: Pfizer, F2G, Cidara, Octapharma, Amplyx, Gilead, Stendhal, Viracor, Abbott, Scynexis, Biotoscana, Astellas, and Mayne